U.S. markets open in 7 hours 32 minutes
  • S&P Futures

    4,222.00
    +8.25 (+0.20%)
     
  • Dow Futures

    33,834.00
    +73.00 (+0.22%)
     
  • Nasdaq Futures

    14,142.25
    +12.25 (+0.09%)
     
  • Russell 2000 Futures

    2,285.30
    +4.40 (+0.19%)
     
  • Crude Oil

    73.56
    -0.10 (-0.14%)
     
  • Gold

    1,782.80
    -0.10 (-0.01%)
     
  • Silver

    25.92
    -0.11 (-0.42%)
     
  • EUR/USD

    1.1896
    -0.0028 (-0.24%)
     
  • 10-Yr Bond

    1.4840
    0.0000 (0.00%)
     
  • Vix

    17.89
    -2.81 (-13.57%)
     
  • GBP/USD

    1.3894
    -0.0039 (-0.28%)
     
  • USD/JPY

    110.4300
    +0.1320 (+0.12%)
     
  • BTC-USD

    32,600.71
    -1,880.01 (-5.45%)
     
  • CMC Crypto 200

    782.45
    -67.89 (-7.98%)
     
  • FTSE 100

    7,062.29
    +44.82 (+0.64%)
     
  • Nikkei 225

    28,851.44
    +840.51 (+3.00%)
     

Trading in Novo Nordisk shares by board members, executives and associated persons on 7 May 2021

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Bagsværd, Denmark, 7 May 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.

Please see the attached PDF document for detailed information about this trading.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Media:

Mette Kruse Danielsen

+45 3079 3883

mkd@novonordisk.com

Michael Bachner (US)

+1 609 664 7308

mzyb@novonordisk.com

Investors:

Daniel Muusmann Bohsen

+45 3075 2175

dabo@novonordisk.com

Valdemar Borum Svarrer

+45 3079 0301

jvls@novonordisk.com

Ann Søndermølle Rendbæk

+45 3075 2253

arnd@novonordisk.com

David Heiberg Landsted

+45 3077 6915

dhel@novonordisk.com

Mark Joseph Root (US)

+1 848 213 3219

mjhr@novonordisk.com

Company announcement No 33 / 2021

Attachment